BCX4430, a Novel Nucleoside Analog, Effectively Treats Yellow Fever in a Hamster Model
Open Access
- 1 November 2014
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 58 (11), 6607-6614
- https://doi.org/10.1128/aac.03368-14
Abstract
No effective antiviral therapies are currently available to treat disease after infection with yellow fever virus (YFV). A Syrian golden hamster model of yellow fever (YF) was used to characterize the effect of treatment with BCX4430, a novel adenosine nucleoside analog. Significant improvement in survival was observed after treatment with BCX4430 at 4 mg/kg of body weight per day dosed intraperitoneally (i.p.) twice daily (BID). Treatment with BCX4430 at 12.5 mg/kg/day administered i.p. BID for 7 days offered complete protection from mortality and also resulted in significant improvement of other YF disease parameters, including weight loss, serum alanine aminotransferase levels (6 days postinfection [dpi]), and viremia (4 dpi). In uninfected hamsters, BCX4430 at 200 mg/kg/day administered i.p. BID for 7 days was well tolerated and did not result in mortality or weight loss, suggesting a potentially wide therapeutic index. Treatment with BCX4430 at 12 mg/kg/day i.p. remained effective when administered once daily and for only 4 days. Moreover, BCX4430 dosed at 200 mg/kg/day i.p. BID for 7 days effectively treated YF, even when treatment was delayed up to 4 days after virus challenge, corresponding with peak viral titers in the liver and serum. BCX4430 treatment did not preclude a protective antibody response, as higher neutralizing antibody (nAb) concentrations corresponded with increasing delays of treatment initiation, and greater nAb responses resulted in the protection of animals from a secondary challenge with YFV. In summary, BCX4430 is highly active in a hamster model of YF, even when treatment is initiated at the peak of viral replication.Keywords
This publication has 19 references indexed in Scilit:
- Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430Nature, 2014
- Treatment of yellow feverAntiviral Research, 2008
- In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus InfectionsAntimicrobial Agents and Chemotherapy, 2007
- Activity of T-1106 in a Hamster Model of Yellow Fever Virus InfectionAntimicrobial Agents and Chemotherapy, 2007
- Comparison of the inhibitory effects of interferon alfacon-1 and ribavirin on yellow fever virus infection in a hamster modelAntiviral Research, 2007
- Yellow Fever: A Disease that Has Yet to be ConqueredAnnual Review of Entomology, 2007
- EXPERIMENTAL YELLOW FEVER VIRUS INFECTION IN THE GOLDEN HAMSTER (MESOCRICETUS AURATUS) III. CLINICAL LABORATORY VALUESThe American Journal of Tropical Medicine and Hygiene, 2006
- EFFICACY OF POST-EXPOSURE TREATMENT OF YELLOW FEVER WITH RIBAVIRIN IN A HAMSTER MODEL OF THE DISEASEThe American Journal of Tropical Medicine and Hygiene, 2004
- Experimental Yellow Fever Virus Infection in the Golden Hamster(Mesocricetus auratus).I. Virologic, Biochemical, and Immunologic StudiesThe Journal of Infectious Diseases, 2001
- Pathophysiologic Correlations in a Rhesus Monkey Model of Yellow FeverThe American Journal of Tropical Medicine and Hygiene, 1981